- Home
- ZAPP vs QNRX Comparison
ZAPP vs QNRX Comparison
Compare ZAPP & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZAPP
- QNRX
- Stock Information
- Founded
- ZAPP 2017
- QNRX 2018
- Country
- ZAPP Thailand
- QNRX United States
- Employees
- ZAPP N/A
- QNRX N/A
- Industry
- ZAPP Motor Vehicles
- QNRX Medical/Dental Instruments
- Sector
- ZAPP Consumer Discretionary
- QNRX Health Care
- Exchange
- ZAPP Nasdaq
- QNRX Nasdaq
- Market Cap
- ZAPP 5.1M
- QNRX 5.3M
- IPO Year
- ZAPP N/A
- QNRX N/A
- Fundamental
- Price
- ZAPP $1.12
- QNRX $0.57
- Analyst Decision
- ZAPP
- QNRX Strong Buy
- Analyst Count
- ZAPP 0
- QNRX 1
- Target Price
- ZAPP N/A
- QNRX $4.00
- AVG Volume (30 Days)
- ZAPP 208.3K
- QNRX 1.4M
- Earning Date
- ZAPP 01-28-2025
- QNRX 03-12-2025
- Dividend Yield
- ZAPP N/A
- QNRX N/A
- EPS Growth
- ZAPP N/A
- QNRX N/A
- EPS
- ZAPP N/A
- QNRX N/A
- Revenue
- ZAPP N/A
- QNRX N/A
- Revenue This Year
- ZAPP N/A
- QNRX N/A
- Revenue Next Year
- ZAPP $53,347.33
- QNRX N/A
- P/E Ratio
- ZAPP N/A
- QNRX N/A
- Revenue Growth
- ZAPP N/A
- QNRX N/A
- 52 Week Low
- ZAPP $0.70
- QNRX $0.43
- 52 Week High
- ZAPP $19.10
- QNRX $6.18
- Technical
- Relative Strength Index (RSI)
- ZAPP 33.87
- QNRX 43.80
- Support Level
- ZAPP $1.20
- QNRX $0.56
- Resistance Level
- ZAPP $1.47
- QNRX $0.63
- Average True Range (ATR)
- ZAPP 0.11
- QNRX 0.07
- MACD
- ZAPP 0.00
- QNRX -0.00
- Stochastic Oscillator
- ZAPP 14.63
- QNRX 11.56
About ZAPP Zapp Electric Vehicles Group Limited
Zapp Electric Vehicles Group Ltd designs manufactures, and sells high-performance electric vehicles, including maintenance and repair of electric vehicles and related parts and accessories.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.